Actinium Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2017 Annual Meeting of Stockholders held by Actinium Pharmaceuticals, Inc. on December 20, 2017. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Of the 80,025,073 shares eligible to vote, 56,499,015 shares (approximately 70.6%) were present in person or by proxy. All four proposals submitted to stockholders were approved:
- Proposal 1 (Director Election): David Nicholson and Richard I. Steinhart were elected as Class I directors for a 36-month term.
- Proposal 2 (Auditor Ratification): GBH CPAs, PC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Proposal 3 (Stock Plan Amendment): An amendment to the 2013 Amended and Restated Stock Plan to increase authorized shares by 5 million was approved.
- Proposal 4 (Charter Amendment): An amendment to the Company's charter to increase the number of authorized common shares to 400 million was approved.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Stockholder participation rate was approximately 70.6%.
- The authorized share count has been increased to 400 million shares.
- The equity incentive plan pool was expanded by 5 million shares.
- GBH CPAs, PC continues as the independent auditor.
- Two new directors were elected to the board for a three-year term.